This Article Full Text (PDF) All Versions of this Article: 1756285609339383v1 1756285609339383v2 2/6/393    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Isaacson, S. H. Articles by Hauser, R. A. Social Bookmarking                         What's this?

Review: Improving symptom control in early Parkinson’s disease

VUniversity of Miami School of Medicine, Miami, FL, Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL, USA, isaacson@ ParkinsonsCenter.org

Robert A. Hauser

Pharmacology and Experimental Therapeutics, Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, FL, USA

Motor symptoms in Parkinson’s disease (PD) are caused by a severe loss of pigmented dopamine-producing nigro-striatal neurons. Symptomatic therapies provide benefit for motor features by restoring dopamine receptor stimulation. Studies have demonstrated that delaying the introduction of dopaminergic medical therapy is associated with a rapid decline in quality of life. Nonmotor symptoms, such as depression, are common in early PD and also affect quality of life. Therefore, dopaminergic therapy should typically be initiated at, or shortly following, diagnosis. Monamine oxidase-B inhibitors provide mild symptomatic benefit, have excellent side effect profiles, and may improve long-term outcomes, making them an important first-line treatment option. Dopamine agonists (DAs) provide moderate symptomatic benefit but are associated with more side effects than levodopa. However, they delay the development of motor complications by delaying the need for levodopa. Levodopa (LD) is the most efficacious medication, but its chronic use is associated with the development of motor complications that can be difficult to resolve. Younger patients are more likely to develop levodopa-induced motor complications and they are therefore often treated with a DA before levodopa is added. For older patients, levodopa provides good motor benefit with a relatively low-risk of motor complications. Using levodopa with a dopa-decarboxylase inhibitor lessens adverse effects, and further adding a catechol-O-methyl transferase inhibitor can improve symptom control.

Key Words: Parkinson’s disease • therapy • levodopa • dopamine agonist • COMT inhibitor • MAO inhibitor

This version was published on November 1, 2009

Therapeutic Advances in Neurological Disorders, Vol. 2, No. 6, 393-400 (2009)
DOI: 10.1177/1756285609339383


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?